1
|
Malaina I, Martinez L, Salcines-Cuevas D, Teran-Navarro H, Ocejo-Vinyals JG, Gonzalez-Lopez E, Soriano V, Ubeda M, Perez Pinilla MB, Martinez de la Fuente I, Alvarez-Dominguez C. Testing a vaccine candidate against Hepatitis C virus designed by combinatorial optimization. Sci Rep 2023; 13:21746. [PMID: 38066027 PMCID: PMC10709393 DOI: 10.1038/s41598-023-48458-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Accepted: 11/27/2023] [Indexed: 12/18/2023] Open
Abstract
This paper presents a new procedure for vaccine design against highly variable viruses such as Hepatitis C. The procedure uses an optimization algorithm to design vaccines that maximize the coverage of epitopes across different virus variants. Weighted epitopes based on the success ratio of immunological assays are used to prioritize the selection of epitopes for vaccine design. The procedure was successfully applied to design DC vaccines loaded with two HCV peptides, STG and DYP, which were shown to be safe, immunogenic, and able to induce significant levels of anti-viral cytokines, peptide-specific cellular immune responses and IgG antibodies. The procedure could potentially be applied to other highly variable viruses that currently lack effective vaccines.
Collapse
Affiliation(s)
- Iker Malaina
- Department of Mathematics, University of the Basque Country (UPV/EHU), 48080, Bilbao, Spain.
- Biocruces Health Research Institute, Bilbao, Spain.
| | - Luis Martinez
- Department of Mathematics, University of the Basque Country (UPV/EHU), 48080, Bilbao, Spain
- Biocruces Health Research Institute, Bilbao, Spain
- Basque Center of Applied Mathematics (BCAM), 48009, Bilbao, Spain
| | - David Salcines-Cuevas
- Facultad de Ciencias de La Salud, Universidad Internacional de La Rioja (UNIR), MEDONLINE Group, Avda. de La Paz, 137, 26006, Logroño, La Rioja, Spain
| | - Hector Teran-Navarro
- Facultad de Ciencias de La Salud, Universidad Internacional de La Rioja (UNIR), MEDONLINE Group, Avda. de La Paz, 137, 26006, Logroño, La Rioja, Spain
| | - J Gonzalo Ocejo-Vinyals
- Servicio de Inmunología, Cantabria and Instituto de Investigación Marqués de Valdecilla (IDIVAL), Hospital Universitario Marqués de Valdecilla, Avda. de Valdecilla S/N, 39008, Santander, Spain
| | - Elena Gonzalez-Lopez
- Servicio de Inmunología, Cantabria and Instituto de Investigación Marqués de Valdecilla (IDIVAL), Hospital Universitario Marqués de Valdecilla, Avda. de Valdecilla S/N, 39008, Santander, Spain
| | - Vicente Soriano
- Facultad de Ciencias de La Salud, Universidad Internacional de La Rioja (UNIR), MEDONLINE Group, Avda. de La Paz, 137, 26006, Logroño, La Rioja, Spain
| | - María Ubeda
- Facultad de Ciencias de La Salud, Universidad Internacional de La Rioja (UNIR), MEDONLINE Group, Avda. de La Paz, 137, 26006, Logroño, La Rioja, Spain
| | | | | | - Carmen Alvarez-Dominguez
- Facultad de Ciencias de La Salud, Universidad Internacional de La Rioja (UNIR), MEDONLINE Group, Avda. de La Paz, 137, 26006, Logroño, La Rioja, Spain.
| |
Collapse
|
2
|
Tadlock S, Phillips CA, Casal ML, Kraus MS, Gelzer AR, Boland MR. Development of an Informatics Algorithm to Link Seasonal Infectious Diseases to Birth-Dependent Diseases Across Species: A Case Study with Osteosarcoma. AMIA JOINT SUMMITS ON TRANSLATIONAL SCIENCE PROCEEDINGS. AMIA JOINT SUMMITS ON TRANSLATIONAL SCIENCE 2021; 2021:585-594. [PMID: 34457174 PMCID: PMC8378620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Many diseases have been linked with birth seasonality, and these fall into four main categories: mental, cardiovascular, respiratory and women's reproductive health conditions. Informatics methods are needed to uncover seasonally varying infectious diseases that may be responsible for the increased birth month-dependent disease risk observed. We have developed a method to link seasonal infectious disease data from the USA to birth month dependent disease data from humans and canines. We also include seasonal air pollution and climate data to determine the seasonal factors most likely involved in the response. We test our method with osteosarcoma, a rare bone cancer. We found the Lyme disease incidence was the most strongly correlated significant factor in explaining the birth month-osteosarcoma disease pattern (R=0.418, p=2.80X10-23), and this was true across all populations observed: canines, pediatric, and adult populations.
Collapse
Affiliation(s)
- Sarah Tadlock
- Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania, Philadelphia, PA, USA
| | - Charles A Phillips
- Cancer Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Margret L Casal
- Department of Clinical Studies and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Marc S Kraus
- Department of Clinical Studies and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Anna R Gelzer
- Department of Clinical Studies and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Mary Regina Boland
- Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
3
|
Teran-Navarro H, Salcines-Cuevas D, Calderon-Gonzalez R, Tobes R, Calvo-Montes J, Pérez-Del Molino Bernal IC, Yañez-Diaz S, Fresno M, Alvarez-Dominguez C. A Comparison Between Recombinant Listeria GAPDH Proteins and GAPDH Encoding mRNA Conjugated to Lipids as Cross-Reactive Vaccines for Listeria, Mycobacterium, and Streptococcus. Front Immunol 2021; 12:632304. [PMID: 33953709 PMCID: PMC8092121 DOI: 10.3389/fimmu.2021.632304] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Accepted: 02/15/2021] [Indexed: 12/29/2022] Open
Abstract
Cross-reactive vaccines recognize common molecular patterns in pathogens and are able to confer broad spectrum protection against different infections. Antigens common to pathogenic bacteria that induce broad immune responses, such as the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) of the genera Listeria, Mycobacterium, or Streptococcus, whose sequences present more than 95% homology at the N-terminal GAPDH1-22 peptide, are putative candidates for universal vaccines. Here, we explore vaccine formulations based on dendritic cells (DC) loaded with two molecular forms of Listeria monocytogenes GAPDH (LM-GAPDH), such as mRNA carriers or recombinant proteins, and compare them with the same molecular forms of three other antigens used in experimental vaccines, listeriolysin O of Listeria monocytogeness, Ag85A of Mycobacterium marinum, and pneumolysin of Streptococcus pneumoniae. DC loaded with LM-GAPDH recombinant proteins proved to be the safest and most immunogenic vaccine vectors, followed by mRNA encoding LM-GAPDH conjugated to lipid carriers. In addition, macrophages lacked sufficient safety as vaccines for all LM-GAPDH molecular forms. The ability of DC loaded with LM-GAPDH recombinant proteins to induce non-specific DC activation explains their adjuvant potency and their capacity to trigger strong CD4+ and CD8+ T cell responses explains their high immunogenicity. Moreover, their capacity to confer protection in vaccinated mice against challenges with L. monocytogenes, M. marinum, or S. pneumoniae validated their efficiency as cross-reactive vaccines. Cross-protection appears to involve the induction of high percentages of GAPDH1-22 specific CD4+ and CD8+ T cells stained for intracellular IFN-γ, and significant levels of peptide-specific antibodies in vaccinated mice. We concluded that DC vaccines loaded with L. monocytogenes GAPDH recombinant proteins are cross-reactive vaccines that seem to be valuable tools in adult vaccination against Listeria, Mycobacterium, and Streptococcus taxonomic groups.
Collapse
Affiliation(s)
| | - David Salcines-Cuevas
- Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain
- Grupo de Oncología y Nanovacunas, Santander, Spain
| | - Ricardo Calderon-Gonzalez
- Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain
- Grupo de Oncología y Nanovacunas, Santander, Spain
| | | | - Jorge Calvo-Montes
- Microbiology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | | | - Sonsoles Yañez-Diaz
- Dermatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
- Facultad de Medicina, Universidad de Cantabria, Santander, Spain
| | - Manuel Fresno
- DIOMUNE S.L., Parque Científico de Madrid, Madrid, Spain
- Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, Madrid, Spain
| | - Carmen Alvarez-Dominguez
- Facultad de Educación y Facultad de Ciencias de la Salud, Universidad Internacional de La Rioja, Logroño, Spain
| |
Collapse
|
4
|
Schijns V, Majhen D, van der Ley P, Thakur A, Summerfield A, Berisio R, Nativi C, Fernández-Tejada A, Alvarez-Dominguez C, Gizurarson S, Zamyatina A, Molinaro A, Rosano C, Jakopin Ž, Gursel I, McClean S. Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation. Pharmaceutics 2021; 13:501. [PMID: 33917629 PMCID: PMC8067490 DOI: 10.3390/pharmaceutics13040501] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2021] [Revised: 03/05/2021] [Accepted: 03/08/2021] [Indexed: 01/21/2023] Open
Abstract
Vaccines are the most effective medical intervention due to their continual success in preventing infections and improving mortality worldwide. Early vaccines were developed empirically however, rational design of vaccines can allow us to optimise their efficacy, by tailoring the immune response. Establishing the immune correlates of protection greatly informs the rational design of vaccines. This facilitates the selection of the best vaccine antigens and the most appropriate vaccine adjuvant to generate optimal memory immune T cell and B cell responses. This review outlines the range of vaccine types that are currently authorised and those under development. We outline the optimal immunological correlates of protection that can be targeted. Finally we review approaches to rational antigen selection and rational vaccine adjuvant design. Harnessing current knowledge on protective immune responses in combination with critical vaccine components is imperative to the prevention of future life-threatening diseases.
Collapse
Affiliation(s)
- Virgil Schijns
- Intravacc, Institute for Translational Vaccinology (Intravacc), Utrecht Science Park, 3721 MA Bilthoven, The Netherlands;
- Epitopoietic Research Corporation (ERC), 5374 RE Schaijk, The Netherlands
| | - Dragomira Majhen
- Laboratory for Cell Biology and Signalling, Division of Molecular Biology, Ruđer Bošković Instiute, HR-10000 Zagreb, Croatia;
| | - Peter van der Ley
- Intravacc, Institute for Translational Vaccinology (Intravacc), Utrecht Science Park, 3721 MA Bilthoven, The Netherlands;
| | - Aneesh Thakur
- Department of Pharmacy, University of Copenhagen, 2100 Copenhagen, Denmark;
| | - Artur Summerfield
- Institute of Virology and Immunology, 3147 Mittelhausern, Switzerland;
- Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, 3001 Bern, Switzerland
| | - Rita Berisio
- Institute of Biostructures and Bioimaging, National Research Council, I-80134 Naples, Italy;
| | - Cristina Nativi
- Department of Chemistry “Ugo Schiff”, University of Florence, 50019 Sesto Fiorentino, Italy;
| | - Alberto Fernández-Tejada
- Chemical Immunology Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Biscay Science and Technology Park, 48160 Derio-Bilbao, Spain;
- Ikerbasque, Basque Foundation for Science, 48009 Bilbao, Spain
| | - Carmen Alvarez-Dominguez
- Facultativo en plantilla (Research Faculty), Instituto de Investigación Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain;
| | - Sveinbjörn Gizurarson
- Faculty of Pharmaceutical Sciences, University of Iceland, 107 Reykjavik, Iceland;
- Department of Pharmacy, College of Medicine, University of Malawi, Blantyre 3, Malawi
| | - Alla Zamyatina
- Department of Chemistry, University of Natural Resources and Life Sciences, 1190 Vienna, Austria;
| | - Antonio Molinaro
- Department of Chemical Sciences, University of Napoli Federico II, Complesso Universitario Monte Santangelo, I-80126 Napoli, Italy;
- Department of Chemistry, School of Science, Osaka University, 1-1 Osaka University Machikaneyama, Toyonaka, Osaka 560-0043, Japan
| | - Camillo Rosano
- Proteomics and Mass Spectrometry Unit, IRCCS Policlinico San Martino, 16132 Genova-1, Italy;
| | - Žiga Jakopin
- Faculty of Pharmacy, University of Ljubljana, 1000 Ljubiljana, Slovenia;
| | - Ihsan Gursel
- Molecular Biology and Genetics Department, Science Faculty, Bilkent University, Bilkent, 06800 Ankara, Turkey;
| | - Siobhán McClean
- School of Biomolecular and Biomedical Sciences, University College Dublin, Belfield, D04 V1W8 Dublin, Ireland
| |
Collapse
|
5
|
Glyceraldehyde-3-phosphate Dehydrogenase Common Peptides of Listeria monocytogenes, Mycobacterium marinum and Streptococcus pneumoniae as Universal Vaccines. Vaccines (Basel) 2021; 9:vaccines9030269. [PMID: 33802959 PMCID: PMC8002646 DOI: 10.3390/vaccines9030269] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2021] [Revised: 03/10/2021] [Accepted: 03/12/2021] [Indexed: 12/22/2022] Open
Abstract
Universal vaccines can be prepared with antigens common to different pathogens. In this regard, the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a common virulence factor among pathogenic bacteria of the genera Listeria, Mycobacterium and Streptococcus. Their N-terminal 22 amino acid peptides, GAPDH-L1 (Listeria), GAPDH-M1 (Mycobacterium) and GAPDH-S1 (Streptococcus), share 95–98.55% sequence homology, biochemical and MHC binding abilities and, therefore, are good candidates for universal vaccine designs. Here, we used dendritic cells (DC) as vaccine platforms to test GAPDH epitopes that conferred protection against Listeria monocytogenes, Mycobacterium marinum or Streptococcus pneumoniae in our search of epitopes for universal vaccines. DC loaded with GAPDH-L1, GAPDH-M1 or GAPDH-S1 peptides show high immunogenicity measured by the cellular DTH responses in mice, lacked toxicity and were capable of cross-protection immunity against mice infections with each one of the pathogens. Vaccine efficiency correlated with high titers of anti-GAPDH-L1 antibodies in sera of vaccinated mice, a Th1 cytokine pattern and high frequencies of GAPDH-L1-specific CD4+ and CD8+ T cells and IFN-γ producers in the spleens. We concluded that GAPDH-L1 peptide was the best epitope for universal vaccines in the Listeria, Mycobacterium or Streptococcus taxonomic groups, whose pathogenic strains caused relevant morbidities in adults and especially in the elderly.
Collapse
|
6
|
Alvarez-Dominguez C, Salcines-Cuevas D, Teran-Navarro H, Calderon-Gonzalez R, Tobes R, Garcia I, Grijalvo S, Paradela A, Seoane A, Sangari FJ, Fresno M, Calvo-Montes J, Pérez Del Molino Bernal IC, Yañez-Diaz S. Epitopes for Multivalent Vaccines Against Listeria, Mycobacterium and Streptococcus spp: A Novel Role for Glyceraldehyde-3-Phosphate Dehydrogenase. Front Cell Infect Microbiol 2020; 10:573348. [PMID: 33194812 PMCID: PMC7657268 DOI: 10.3389/fcimb.2020.573348] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Accepted: 09/30/2020] [Indexed: 12/11/2022] Open
Abstract
The glycolytic enzyme and bacterial virulence factor of Listeria monocytogenes, the glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Lmo2459), ADP-ribosylated the small GTPase, Rab5a, and blocked phagosome maturation. This inhibitory activity localized within the NAD binding domain of GAPDH at the N-terminal 1–22 peptides, also conferred listeriosis protection when used in dendritic cell-based vaccines. In this study, we explore GAPDH of Listeria, Mycobacterium, and Streptococcus spp. taxonomic groups to search for epitopes that confer broad protection against pathogenic strains of these bacteria. GAPDH multivalent epitopes are selected if they induce inhibitory actions and wide-ranging immune responses. Proteomic isolation of GAPDH from dendritic cells infected with Listeria, Mycobacterium, or Streptococcus confirmed similar enzymatic, Rab5a inhibitory and immune stimulation abilities. We identified by bioinformatics and functional analyses GAPDH N-terminal 1–22 peptides from Listeria, Mycobacterium, and Streptococcus that shared 95% sequence homology, enzymatic activity, and B and T cell immune domains. Sera obtained from patients or mice infected with hypervirulent pathogenic Listeria, Mycobacterium, or Streptococcus presented high levels of anti-GAPDH 1–22 antibodies and Th2 cytokines. Monocyte derived dendritic cells from healthy donors loaded with GAPDH 1–22 peptides from Listeria, Mycobacterium, or Streptococcus showed activation patterns that correspond to cross-immunity abilities. In summary, GAPDH 1–22 peptides appeared as putative candidates to include in multivalent dendritic based vaccine platforms for Listeria, Mycobacterium, or Streptococcus.
Collapse
Affiliation(s)
- Carmen Alvarez-Dominguez
- Grupo de Oncología y Nanovacunas, Instituto de Investigación Marqués de Valdecilla, Santander, Spain.,Facultad de Educación, Universidad Internacional de La Rioja, Logroño, Spain
| | - David Salcines-Cuevas
- Grupo de Oncología y Nanovacunas, Instituto de Investigación Marqués de Valdecilla, Santander, Spain
| | - Héctor Teran-Navarro
- Grupo de Oncología y Nanovacunas, Instituto de Investigación Marqués de Valdecilla, Santander, Spain
| | - Ricardo Calderon-Gonzalez
- Grupo de Oncología y Nanovacunas, Instituto de Investigación Marqués de Valdecilla, Santander, Spain
| | | | - Isabel Garcia
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.,CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain
| | - Santiago Grijalvo
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.,Department of Surfactants and Nanobiotechnology, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain
| | | | - Asunción Seoane
- Department of Molecular Biology, Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC, CSIC-Universidad de Cantabria-SODERCAN), Santander, Spain.,Facultad de Medicina, Universidad de Cantabria, Santander, Spain
| | - Felix J Sangari
- Department of Molecular Biology, Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC, CSIC-Universidad de Cantabria-SODERCAN), Santander, Spain.,Facultad de Medicina, Universidad de Cantabria, Santander, Spain
| | - Manuel Fresno
- Department of Molecular Biology, DIOMUNE S.L., Madrid, Spain.,Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, Madrid, Spain
| | - Jorge Calvo-Montes
- Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | | | - Sonsoles Yañez-Diaz
- Grupo de Oncología y Nanovacunas, Instituto de Investigación Marqués de Valdecilla, Santander, Spain.,Servicio de Dermatología, Hospital Universitario Marqués de Valdecilla, Santander, Spain.,Departamento de Medicina y Cirugia, Facultad de Medicina, Universidad de Cantabria, Santander, Spain
| |
Collapse
|
7
|
Phelps CC, Vadia S, Boyaka PN, Varikuti S, Attia Z, Dubey P, Satoskar AR, Tweten R, Seveau S. A listeriolysin O subunit vaccine is protective against Listeria monocytogenes. Vaccine 2020; 38:5803-5813. [PMID: 32684498 DOI: 10.1016/j.vaccine.2020.06.049] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2019] [Revised: 05/12/2020] [Accepted: 06/18/2020] [Indexed: 12/15/2022]
Abstract
Listeria monocytogenes is a facultative intracellular pathogen responsible for the life-threatening disease listeriosis. The pore-forming toxin listeriolysin O (LLO) is a critical virulence factor that plays a major role in the L. monocytogenes intracellular lifecycle and is indispensable for pathogenesis. LLO is also a dominant antigen for T cells involved in sterilizing immunity and it was proposed that LLO acts as a T cell adjuvant. In this work, we generated a novel full-length LLO toxoid (LLOT) in which the cholesterol-recognition motif, a threonine-leucine pair located at the tip of the LLO C-terminal domain, was substituted with two glycine residues. We showed that LLOT lost its ability to bind cholesterol and to form pores. Importantly, LLOT retained binding to the surface of epithelial cells and macrophages, suggesting that it could efficiently be captured by antigen-presenting cells. We then determined if LLOT can be used as an antigen and adjuvant to protect mice from L. monocytogenes infection. Mice were immunized with LLOT alone or together with cholera toxin or Alum as adjuvants. We found that mice immunized with LLOT alone or in combination with the Th2-inducing adjuvant Alum were not protected against L. monocytogenes. On the other hand, mice immunized with LLOT along with the experimental adjuvant cholera toxin, were protected against L. monocytogenes, as evidenced by a significant decrease in bacterial burden in the liver and spleen three days post-infection. This immunization regimen elicited mixed Th1, Th2, and Th17 responses, as well as the generation of LLO-neutralizing antibodies. Further, we identified T cells as being required for immunization-induced reductions in bacterial burden, whereas B cells were dispensable in our model of non-pregnant young mice. Overall, this work establishes that LLOT is a promising vaccine antigen for the induction of protective immunity against L. monocytogenes by subunit vaccines containing Th1-driving adjuvants.
Collapse
Affiliation(s)
- Christopher C Phelps
- Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA; Department of Microbiology, The Ohio State University, The Ohio State University, Columbus, OH, USA
| | - Stephen Vadia
- Department of Microbiology, The Ohio State University, The Ohio State University, Columbus, OH, USA; Department of Biology, Washington University in St. Louis, MO 63130, USA
| | - Prosper N Boyaka
- Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA; Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA
| | - Sanjay Varikuti
- Department of Pathology, The Ohio State University, Columbus, OH, USA
| | - Zayed Attia
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA
| | - Purnima Dubey
- Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA
| | - Abhay R Satoskar
- Department of Pathology, The Ohio State University, Columbus, OH, USA
| | - Rodney Tweten
- Department of Microbial & Immunology, University of Oklahoma, Oklahoma City, OK, USA
| | - Stephanie Seveau
- Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA; Department of Microbiology, The Ohio State University, The Ohio State University, Columbus, OH, USA.
| |
Collapse
|
8
|
Kopeckova M, Pavkova I, Stulik J. Diverse Localization and Protein Binding Abilities of Glyceraldehyde-3-Phosphate Dehydrogenase in Pathogenic Bacteria: The Key to its Multifunctionality? Front Cell Infect Microbiol 2020; 10:89. [PMID: 32195198 PMCID: PMC7062713 DOI: 10.3389/fcimb.2020.00089] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Accepted: 02/19/2020] [Indexed: 12/12/2022] Open
Abstract
Bacterial proteins exhibiting two or more unrelated functions, referred to as moonlighting proteins, are suggested to contribute to full virulence manifestation in pathogens. An expanding number of published studies have revealed the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to be a multitasking protein with virulence impact in a number of pathogenic bacteria. This protein can be detected on the bacterial surface or outside the bacterial cell, where it interacts with host proteins. In this way, GAPDH is able to modulate various pathogenic processes. Moreover, it has been shown to be involved in non-enzymatic processes inside the bacterial cell. In this mini review, we summarize main findings concerning the multiple localization and protein interactions of GAPDH derived from bacterial pathogens of humans. We also briefly discuss problems associated with using GAPDH as a vaccine antigen and endeavor to inspire further research to fill gaps in the existing knowledge.
Collapse
Affiliation(s)
- Monika Kopeckova
- Department of Molecular Pathology and Biology, Faculty of Military Health Science, University of Defence, Hradec Kralove, Czechia
| | - Ivona Pavkova
- Department of Molecular Pathology and Biology, Faculty of Military Health Science, University of Defence, Hradec Kralove, Czechia
| | - Jiri Stulik
- Department of Molecular Pathology and Biology, Faculty of Military Health Science, University of Defence, Hradec Kralove, Czechia
| |
Collapse
|
9
|
Stout A, Van Stelten-Carlson A, Marquis H, Ballou M, Reilly B, Loneragan GH, Nightingale K, Ivanek R. Public health impact of foodborne exposure to naturally occurring virulence-attenuated Listeria monocytogenes: inference from mouse and mathematical models. Interface Focus 2020; 10:20190046. [PMID: 31897288 PMCID: PMC6936009 DOI: 10.1098/rsfs.2019.0046] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/30/2019] [Indexed: 12/16/2022] Open
Abstract
Listeriosis is a clinically severe foodborne disease caused by Listeria monocytogenes (Lm). However, approximately 45% of Lm isolates in food carry a virulence-attenuating single-nucleotide polymorphism in inlA, which normally facilitates crossing the intestinal barrier during the initial stages of infection. We hypothesized that (i) natural exposure to virulence-attenuated (vA) Lm strains through food can confer protective immunity against listeriosis attributable to fully virulent (fV) strains and (ii) current food safety measures to minimize exposure to both Lm strains may have adverse population-level outcomes. To test these hypotheses, we evaluated the host response to Lm in a mouse infection model and through mathematical modelling in a human population. After oral immunization with a murinized vA Lm strain, we demonstrated the elicitation of a CD8+ T-cell response and protection against subsequent challenge with an fV strain. A two-strain compartmental mathematical model of human exposure to Lm with cross-protective immunity was also developed. If food safety testing strategies preferentially identify and remove food contaminated by vA strains (potentially due to their common occurrence in foods and higher concentration in food compared to fV strains), the model predicted minimal public health benefit to potentially adverse effects. For example, reducing vA exposures by half, while maintaining fV exposures results in an approximately 6% rise in annual incidence.
Collapse
Affiliation(s)
- Alison Stout
- Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY, USA
| | | | - Hélène Marquis
- Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA
| | - Michael Ballou
- Department of Veterinary Sciences, Texas Tech University, Lubbock, TX, USA
| | - Brian Reilly
- Department of Biological Sciences, Texas Tech University, Lubbock, TX, USA
- Department of Immunology and Microbiology, Texas Tech University Health Sciences Center, Lubbock, TX, USA
| | - Guy H. Loneragan
- Department of Animal and Food Sciences, Texas Tech University, Lubbock, TX, USA
- School of Veterinary Medicine, Texas Tech University, Amarillo, TX, USA
| | - Kendra Nightingale
- Department of Animal and Food Sciences, Texas Tech University, Lubbock, TX, USA
| | - Renata Ivanek
- Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY, USA
| |
Collapse
|
10
|
Lu YC, Chuang CH, Chuang KH, Chen IJ, Huang BC, Lee WH, Wang HE, Li JJ, Cheng YA, Cheng KW, Wang JY, Hsieh YC, Lin WW, Cheng TL. Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy. PLoS Biol 2019; 17:e3000286. [PMID: 31194726 PMCID: PMC6563948 DOI: 10.1371/journal.pbio.3000286] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2018] [Accepted: 05/10/2019] [Indexed: 12/15/2022] Open
Abstract
During rheumatoid arthritis (RA) treatment, long-term injection of antitumor necrosis factor α antibodies (anti-TNFα Abs) may induce on-target toxicities, including severe infections (tuberculosis [TB] or septic arthritis) and malignancy. Here, we used an immunoglobulin G1 (IgG1) hinge as an Ab lock to cover the TNFα-binding site of Infliximab by linking it with matrix metalloproteinase (MMP) -2/9 substrate to generate pro-Infliximab that can be specifically activated in the RA region to enhance the selectivity and safety of treatment. The Ab lock significantly inhibits the TNFα binding and reduces the anti-idiotypic (anti-Id) Ab binding to pro-Infliximab by 395-fold, 108-fold compared with Infliximab, respectively, and MMP-2/9 can completely restore the TNFα neutralizing ability of pro-Infliximab to block TNFα downstream signaling. Pro-Infliximab was only selectively activated in the disease site (mouse paws) and presented similar pharmacokinetics (PKs) and bio-distribution to Infliximab. Furthermore, pro-Infliximab not only provided equivalent therapeutic efficacy to Infliximab but also maintained mouse immunity against Listeria infection in the RA mouse model, leading to a significantly higher survival rate (71%) than that of the Infliximab treatment group (0%). The high-selectivity pro-Infliximab maintains host immunity and keeps the original therapeutic efficiency, providing a novel strategy for RA therapy. During treatment of rheumatoid arthritis, systemic administration of anti-TNFα antibodies may induce on-target toxicities, limiting their application. The incorporation of IgG1 hinge as an antibody lock generates a pro-Infliximab whose activation is specific to the disease region, enabling safer RA therapy.
Collapse
Affiliation(s)
- Yun-Chi Lu
- Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Chih-Hung Chuang
- Department of Medical Laboratory Science and Biotechnology, College of Health Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan
- Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Kuo-Hsiang Chuang
- Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei, Taiwan
| | - I-Ju Chen
- Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan
- Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Bo-Cheng Huang
- Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan
| | - Wen-Han Lee
- Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Hsin-Ell Wang
- Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan
- Biophotonics and Molecular Imaging Research Center, National Yang-Ming University, Taipei, Taiwan
| | - Jia-Je Li
- Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan
| | - Yi-An Cheng
- Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Kai-Wen Cheng
- Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Jaw-Yuan Wang
- Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
- Division of Gastroenterology and General Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Yuan-Chin Hsieh
- Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Wen-Wei Lin
- Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
- Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan
- Department of Laboratory Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
- * E-mail: (WWL); (TLC)
| | - Tian-Lu Cheng
- Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
- Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan
- Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan
- Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
- * E-mail: (WWL); (TLC)
| |
Collapse
|
11
|
Martínez L, Milanič M, Malaina I, Álvarez C, Pérez MB, M. de la Fuente I. Weighted lambda superstrings applied to vaccine design. PLoS One 2019; 14:e0211714. [PMID: 30735507 PMCID: PMC6368308 DOI: 10.1371/journal.pone.0211714] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Accepted: 01/19/2019] [Indexed: 11/23/2022] Open
Abstract
We generalize the notion of λ-superstrings, presented in a previous paper, to the notion of weighted λ-superstrings. This generalization entails an important improvement in the applications to vaccine designs, as it allows epitopes to be weighted by their immunogenicities. Motivated by these potential applications of constructing short weighted λ-superstrings to vaccine design, we approach this problem in two ways. First, we formalize the problem as a combinatorial optimization problem (in fact, as two polynomially equivalent problems) and develop an integer programming (IP) formulation for solving it optimally. Second, we describe a model that also takes into account good pairwise alignments of the obtained superstring with the input strings, and present a genetic algorithm that solves the problem approximately. We apply both algorithms to a set of 169 strings corresponding to the Nef protein taken from patiens infected with HIV-1. In the IP-based algorithm, we take the epitopes and the estimation of the immunogenicities from databases of experimental epitopes. In the genetic algorithm we take as candidate epitopes all 9-mers present in the 169 strings and estimate their immunogenicities using a public bioinformatics tool. Finally, we used several bioinformatic tools to evaluate the properties of the candidates generated by our method, which indicated that we can score high immunogenic λ-superstrings that at the same time present similar conformations to the Nef virus proteins.
Collapse
Affiliation(s)
- Luis Martínez
- Department of Mathematics, University of the Basque Country UPV/EHU, Bilbao, Spain
- Biocruces Bizkaia Health Research Institute, Barakaldo, Spain
- Basque Center for Applied Mathematics BCAM, Bilbao, Spain
- * E-mail:
| | - Martin Milanič
- University of Primorska, UP IAM and UP FAMNIT, Koper, Slovenia
| | - Iker Malaina
- Department of Mathematics, University of the Basque Country UPV/EHU, Bilbao, Spain
- Biocruces Bizkaia Health Research Institute, Barakaldo, Spain
| | - Carmen Álvarez
- IDIVAL Valdecilla Biomedical Research Institute, Santander, Spain
| | - Martín-Blas Pérez
- Department of Mathematics, University of the Basque Country UPV/EHU, Bilbao, Spain
| | - Ildefonso M. de la Fuente
- Department of Mathematics, University of the Basque Country UPV/EHU, Bilbao, Spain
- Department of Nutrition, CEBAS-CSIC Institute, Murcia, Spain
| |
Collapse
|
12
|
Calderon-Gonzalez R, Bronchalo-Vicente L, Freire J, Frande-Cabanes E, Alaez-Alvarez L, Gomez-Roman J, Yañez-Diaz S, Alvarez-Dominguez C. Exceptional antineoplastic activity of a dendritic-cell-targeted vaccine loaded with a Listeria peptide proposed against metastatic melanoma. Oncotarget 2017; 7:16855-65. [PMID: 26942874 PMCID: PMC4941355 DOI: 10.18632/oncotarget.7806] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Accepted: 02/09/2016] [Indexed: 01/24/2023] Open
Abstract
Vaccination with dendritic cells (DCs) is proposed to induce lasting responses against melanoma but its survival benefit in patients needs to be demonstrated. We propose a DC-targeted vaccine loaded with a Listeria peptide with exceptional anti-tumour activity to prevent metastasis of melanoma. Mice vaccinated with vaccines based on DCs loaded with listeriolysin O peptide (91–99) (LLO91–99) showed clear reduction of metastatic B16OVA melanoma size and adhesion, prevention of lung metastasis, enhanced survival, and reversion of immune tolerance. Robust innate and specific immune responses explained the efficiency of DC-LLO91–99 vaccines against B16OVA melanoma. The noTable features of this vaccine related to melanoma reduction were: expansion of immune-dominant LLO91–99-specific CD8 T cells that helped to expand melanoma-specific CD8+ T cells; high numbers of tumour-infiltrating lymphocytes with a cytotoxic phenotype; and a decrease in CD4+CD25high regulatory T cells. This vaccine might be a useful alternative treatment for advanced melanoma, alone or in combination with other therapies.
Collapse
Affiliation(s)
- Ricardo Calderon-Gonzalez
- Group of Genomics, Proteomics and Vaccines, Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain
| | - Lucia Bronchalo-Vicente
- Group of Genomics, Proteomics and Vaccines, Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain.,Dermatology Department, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain
| | - Javier Freire
- Pathological Anatomy Department, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain
| | - Elisabet Frande-Cabanes
- Group of Genomics, Proteomics and Vaccines, Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain
| | - Lidia Alaez-Alvarez
- Group of Genomics, Proteomics and Vaccines, Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain
| | - Javier Gomez-Roman
- Pathological Anatomy Department, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain
| | - Sonsóles Yañez-Diaz
- Dermatology Department, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain
| | - Carmen Alvarez-Dominguez
- Group of Genomics, Proteomics and Vaccines, Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain
| |
Collapse
|
13
|
Calderon-Gonzalez R, Terán-Navarro H, García I, Marradi M, Salcines-Cuevas D, Yañez-Diaz S, Solis-Angulo A, Frande-Cabanes E, Fariñas MC, Garcia-Castaño A, Gomez-Roman J, Penades S, Rivera F, Freire J, Álvarez-Domínguez C. Gold glyconanoparticles coupled to listeriolysin O 91-99 peptide serve as adjuvant therapy against melanoma. NANOSCALE 2017; 9:10721-10732. [PMID: 28714508 DOI: 10.1039/c7nr02494k] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Dendritic cell-based (DC-based) vaccines are promising immunotherapies for cancer. However, several factors, such as the lack of efficient targeted delivery and the sources and types of DCs, have limited the efficacy of DCs and their clinical potential. We propose an alternative nanotechnology-based vaccine platform with antibacterial prophylactic abilities that uses gold glyconanoparticles coupled to listeriolysin O 91-99 peptide (GNP-LLO91-99), which acts as a novel adjuvant for cancer therapy. GNP-LLO91-99, when used to vaccinate mice, exhibited dual antitumour activities, namely, the inhibition of tumour migration and growth and adjuvant activity for recruiting and activating DCs, including those from melanoma patients. GNP-LLO91-99 nanoparticles caused tumour apoptosis and induced antigen- and melanoma-specific cytotoxic Th1 responses (P ≤ 0.5). We propose this adjuvant nanotherapy for preventing the progression of the first stages of melanoma.
Collapse
Affiliation(s)
- R Calderon-Gonzalez
- Grupo de Nanovacunas y vacunas celulares basadas en Listeria y sus aplicaciones en biomedicina, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Avda. Cardenal Herrera Oria s/n, 39011 Santander, Cantabria, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
GNP-GAPDH 1-22 nanovaccines prevent neonatal listeriosis by blocking microglial apoptosis and bacterial dissemination. Oncotarget 2017; 8:53916-53934. [PMID: 28903312 PMCID: PMC5589551 DOI: 10.18632/oncotarget.19405] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Accepted: 07/01/2017] [Indexed: 12/12/2022] Open
Abstract
Clinical cases of neonatal listeriosis are associated with brain disease and fetal loss due to complications in early or late pregnancy, which suggests that microglial function is altered. This is believed to be the first study to link microglial apoptosis with neonatal listeriosis and listeriosis-associated brain disease, and to propose a new nanovaccine formulation that reverses all effects of listeriosis and confers Listeria monocytogenes (LM)-specific immunity. We examined clinical cases of neonatal listeriosis in 2013–2015 and defined two useful prognostic immune biomarkers to design listeriosis vaccines: high anti-GAPDH1-22 titres and tumor necrosis factor (TNF)/interleukin (IL)-6 ratios. Therefore, we developed a nanovaccine with gold glyco-nanoparticles conjugated to LM peptide 1-22 of GAPDH (Lmo2459), GNP-GAPDH1-22 nanovaccinesformulated with a pro-inflammatory Toll-like receptor 2/4-targeted adjuvant. Neonates born to non-vaccinated pregnant mice with listeriosis, showed brain and vascular diseases and significant microglial dysfunction by induction of TNF-α-mediated apoptosis. This programmed TNF-mediated suicide explains LM dissemination in brains and livers and blocks production of early pro-inflammatory cytokines such as IL-1β and interferon-α/β. In contrast, neonates born to GNP-GAPDH1–22-vaccinated mothers before LM infection, did not develop listeriosis or brain diseases and had functional microglia. In nanovaccinated mothers, immune responses shifted towards Th1/IL-12 pro-inflammatory cytokine profiles and high production of anti-GAPDH1–22 antibodies, suggesting good induction of LM-specific memory.
Collapse
|
15
|
Calderon-Gonzalez R, Teran-Navarro H, Marimon JM, González-Rico C, Calvo-Montes J, Frande-Cabanes E, Alkorta-Gurrutxaga M, Fariñas MC, Martínez-Martínez L, Perez-Trallero E, Alvarez-Dominguez C. Biomarker Tools to Design Clinical Vaccines Determined from a Study of Annual Listeriosis Incidence in Northern Spain. Front Immunol 2016; 7:541. [PMID: 27965668 PMCID: PMC5126465 DOI: 10.3389/fimmu.2016.00541] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2016] [Accepted: 11/16/2016] [Indexed: 12/23/2022] Open
Abstract
Two regions of northern Spain, Gipuzkoa, and Cantabria present high annual incidence of listeriosis (1.86 and 1.71 cases per 100,000 inhabitants, respectively). We report that the high annual incidences are a consequence of infection with highly virulent Listeria monocytogenes isolates linked to fatal outcomes in elderly patients with cancer. In addition, listeriosis patients with cancer present low IL-17A/IL-6 ratios and significantly reduced levels of anti-GAPDH1–22 antibodies, identified as two novel biomarkers of poor prognosis. Analysis of these biomarkers may aid in reducing the incidence of listeriosis. Moreover, GAPDH1–22-activated monocyte-derived dendritic cells of listeriosis patients with cancer seem useful tools to prepare clinical vaccines as they produce mainly Th1 cytokines.
Collapse
Affiliation(s)
- Ricardo Calderon-Gonzalez
- Grupo de Nanovacunas y vacunas celulares basadas en Listeria y sus aplicaciones en biomedicine, Instituto de Investigación Marqués de Valdecilla (IDIVAL) , Santander , Spain
| | - Hector Teran-Navarro
- Grupo de Nanovacunas y vacunas celulares basadas en Listeria y sus aplicaciones en biomedicine, Instituto de Investigación Marqués de Valdecilla (IDIVAL) , Santander , Spain
| | - José María Marimon
- Servicio de Microbiología, Instituto de Investigación Sanitaria Biodonostia, Hospital Universitario Donostia, San Sebastián, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Claudia González-Rico
- Sección de Enfermedades Infecciosas, Hospital Universitario Marques de Valdecilla , Santander , Spain
| | - Jorge Calvo-Montes
- Servicio de Microbiología, Hospital Universitario Marques de Valdecilla , Santander , Spain
| | - Elisabet Frande-Cabanes
- Grupo de Nanovacunas y vacunas celulares basadas en Listeria y sus aplicaciones en biomedicine, Instituto de Investigación Marqués de Valdecilla (IDIVAL) , Santander , Spain
| | - Miriam Alkorta-Gurrutxaga
- Servicio de Microbiología, Instituto de Investigación Sanitaria Biodonostia, Hospital Universitario Donostia, San Sebastián, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - M C Fariñas
- Sección de Enfermedades Infecciosas, Hospital Universitario Marques de Valdecilla, Santander, Spain; Departamento de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Spain
| | - Luis Martínez-Martínez
- Servicio de Microbiología, Hospital Universitario Marques de Valdecilla, Santander, Spain; Departamento de Biología Molecular, Universidad de Cantabria, Santander, Spain
| | - Emilio Perez-Trallero
- Servicio de Microbiología, Instituto de Investigación Sanitaria Biodonostia, Hospital Universitario Donostia, San Sebastián, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Carmen Alvarez-Dominguez
- Grupo de Nanovacunas y vacunas celulares basadas en Listeria y sus aplicaciones en biomedicine, Instituto de Investigación Marqués de Valdecilla (IDIVAL) , Santander , Spain
| |
Collapse
|
16
|
Calderón-Gonzalez R, Terán-Navarro H, Frande-Cabanes E, Ferrández-Fernández E, Freire J, Penadés S, Marradi M, García I, Gomez-Román J, Yañez-Díaz S, Álvarez-Domínguez C. Pregnancy Vaccination with Gold Glyco-Nanoparticles Carrying Listeria monocytogenes Peptides Protects against Listeriosis and Brain- and Cutaneous-Associated Morbidities. NANOMATERIALS 2016; 6:nano6080151. [PMID: 28335280 PMCID: PMC5224619 DOI: 10.3390/nano6080151] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/16/2016] [Revised: 07/26/2016] [Accepted: 08/12/2016] [Indexed: 01/12/2023]
Abstract
Listeriosis is a fatal infection for fetuses and newborns with two clinical main morbidities in the neonatal period, meningitis and diffused cutaneous lesions. In this study, we vaccinated pregnant females with two gold glyconanoparticles (GNP) loaded with two peptides, listeriolysin peptide 91-99 (LLO91-99) or glyceraldehyde-3-phosphate dehydrogenase 1-22 peptide (GAPDH1-22). Neonates born to vaccinated mothers were free of bacteria and healthy, while non-vaccinated mice presented clear brain affections and cutaneous diminishment of melanocytes. Therefore, these nanoparticle vaccines are effective measures to offer pregnant mothers at high risk of listeriosis interesting therapies that cross the placenta.
Collapse
Affiliation(s)
- Ricardo Calderón-Gonzalez
- Grupo de Nanovacunas y Vaculas Celulares Basadas en Listeria y Sus Aplicaciones en Biomedicina, Instituto de Investigación Marqués de Valdecilla, Avda. Cardenal Herrera Oria S/N, 39011 Santander, Cantabria, Spain.
| | - Héctor Terán-Navarro
- Grupo de Nanovacunas y Vaculas Celulares Basadas en Listeria y Sus Aplicaciones en Biomedicina, Instituto de Investigación Marqués de Valdecilla, Avda. Cardenal Herrera Oria S/N, 39011 Santander, Cantabria, Spain.
| | - Elisabet Frande-Cabanes
- Grupo de Nanovacunas y Vaculas Celulares Basadas en Listeria y Sus Aplicaciones en Biomedicina, Instituto de Investigación Marqués de Valdecilla, Avda. Cardenal Herrera Oria S/N, 39011 Santander, Cantabria, Spain.
| | - Eva Ferrández-Fernández
- Grupo de Nanovacunas y Vaculas Celulares Basadas en Listeria y Sus Aplicaciones en Biomedicina, Instituto de Investigación Marqués de Valdecilla, Avda. Cardenal Herrera Oria S/N, 39011 Santander, Cantabria, Spain.
| | - Javier Freire
- Servicio de Anatomía Patológica, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla 25, 39008 Santander, Cantabria, Spain.
| | - Soledad Penadés
- CIC-biomaGUNE. P de Miramon, 20009 San Sebastian, Gipuzcoa, Spain.
- Biomedical Research Networking Center in Bioingeneering, Nanomaterials and Nanomedine (CIBER-BBN), P de Miramon 182, 20009 San Sebastian, Gipuzkoa, Spain.
| | - Marco Marradi
- CIC-biomaGUNE. P de Miramon, 20009 San Sebastian, Gipuzcoa, Spain.
- Biomedical Research Networking Center in Bioingeneering, Nanomaterials and Nanomedine (CIBER-BBN), P de Miramon 182, 20009 San Sebastian, Gipuzkoa, Spain.
- Servicio de Dermatología, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla 25, 39008 Santander, Cantabria, Spain.
| | - Isabel García
- CIC-biomaGUNE. P de Miramon, 20009 San Sebastian, Gipuzcoa, Spain.
- Biomedical Research Networking Center in Bioingeneering, Nanomaterials and Nanomedine (CIBER-BBN), P de Miramon 182, 20009 San Sebastian, Gipuzkoa, Spain.
| | - Javier Gomez-Román
- Servicio de Anatomía Patológica, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla 25, 39008 Santander, Cantabria, Spain.
| | - Sonsoles Yañez-Díaz
- Servicio de Dermatología, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla 25, 39008 Santander, Cantabria, Spain.
| | - Carmen Álvarez-Domínguez
- Grupo de Nanovacunas y Vaculas Celulares Basadas en Listeria y Sus Aplicaciones en Biomedicina, Instituto de Investigación Marqués de Valdecilla, Avda. Cardenal Herrera Oria S/N, 39011 Santander, Cantabria, Spain.
| |
Collapse
|
17
|
Calderon-Gonzalez R, Marradi M, Garcia I, Petrovsky N, Alvarez-Dominguez C. Novel nanoparticle vaccines for Listeriosis. Hum Vaccin Immunother 2016; 11:2501-3. [PMID: 26252360 PMCID: PMC4635887 DOI: 10.1080/21645515.2015.1063756] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
In recent years, nanomedicine has transformed many areas of traditional medicine, and enabled fresh insights into the prevention of previously difficult to treat diseases. An example of the transformative power of nanomedicine is a recent nano-vaccine against listeriosis, a serious bacterial infection affecting not only pregnant women and their neonates, but also immune-compromised patients with neoplastic or chronic autoimmune diseases. There is a major unmet need for an effective and safe vaccine against listeriosis, with the challenge that an effective vaccine needs to generate protective T cell immunity, a hitherto difficult to achieve objective. Now utilizing a gold nanoparticle antigen delivery approach together with a novel polysaccharide nanoparticulate adjuvant, an effective T-cell vaccine has been developed that provides robust protection in animal models of listeriosis, raising the hope that one day this nanovaccine technology may protect immune-compromised humans against this serious opportunistic infection.
Collapse
Affiliation(s)
- Ricardo Calderon-Gonzalez
- a Grupo de Genómica; Proteómica y Vacunas; Instituto de Investigación Marqués de Valdecilla ; Santander , Spain
| | - Marco Marradi
- b Fundacion Cidetc; Parque Tecnológico ; San Sebastian , Spain
| | - Isabel Garcia
- c CIC-biomaGUNE; Parque Tecnologico ; San Sebastian , Spain
| | - Nikolai Petrovsky
- d Flinders University ; Adelaide , Australia.,e Vaxine Ltd.; Flinders Medical Center ; Adelaide , Australia
| | - Carmen Alvarez-Dominguez
- a Grupo de Genómica; Proteómica y Vacunas; Instituto de Investigación Marqués de Valdecilla ; Santander , Spain
| |
Collapse
|
18
|
Ansari MA, Zia Q, Kazmi S, Ahmad E, Azhar A, Johnson KE, Zubair S, Owais M. Efficacy of Cell Wall-Deficient Spheroplasts Against Experimental Murine Listeriosis. Scand J Immunol 2015; 82:10-24. [DOI: 10.1111/sji.12296] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Accepted: 03/09/2015] [Indexed: 01/19/2023]
Affiliation(s)
- M. A. Ansari
- Interdisciplinary Biotechnology Unit; Aligarh Muslim University; Aligarh India
- Department of Microbiology and Immunology; Rosalind Franklin University of Medicine and Science; North Chicago IL USA
| | - Q. Zia
- Interdisciplinary Biotechnology Unit; Aligarh Muslim University; Aligarh India
| | - S. Kazmi
- Interdisciplinary Biotechnology Unit; Aligarh Muslim University; Aligarh India
| | - E. Ahmad
- Interdisciplinary Biotechnology Unit; Aligarh Muslim University; Aligarh India
| | - A. Azhar
- Interdisciplinary Biotechnology Unit; Aligarh Muslim University; Aligarh India
| | - K. E. Johnson
- Department of Microbiology and Immunology; Rosalind Franklin University of Medicine and Science; North Chicago IL USA
| | - S. Zubair
- Women's College; Aligarh Muslim University; Aligarh India
| | - M. Owais
- Interdisciplinary Biotechnology Unit; Aligarh Muslim University; Aligarh India
| |
Collapse
|
19
|
Calderon-Gonzalez R, Tobes R, Pareja E, Frande-Cabanes E, Petrovsky N, Alvarez-Dominguez C. Identification and characterisation of T-cell epitopes for incorporation into dendritic cell-delivered Listeria vaccines. J Immunol Methods 2015; 424:111-9. [PMID: 26031451 PMCID: PMC7127673 DOI: 10.1016/j.jim.2015.05.009] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2015] [Revised: 05/25/2015] [Accepted: 05/26/2015] [Indexed: 01/05/2023]
Abstract
Dendritic cells loaded with antigenic peptides, because of their safety and robust immune stimulation, would be ideal for induction of immunity to protect against listeriosis. However, there is no currently accepted method to predict which peptides derived from the Listeria proteome might confer protection. While elution of peptides from MHC molecules after Listeria infection yields high-affinity immune-dominant epitopes, these individual epitopes did not reliably confer Listeria protection. Instead we applied bioinformatic predictions of MHC class I and II epitopes to generate antigenic peptides that were then formulated with Advax™, a novel polysaccharide particulate adjuvant able to enhance cross-presentation prior to being screened for their ability to induce protective T-cell responses. A combination of at least four intermediate strength MHC-I binding epitopes and one weak MHC-II binding epitope when expressed in a single peptide sequence and formulated with Advax adjuvant induced a potent T-cell response and high TNF-α and IL-12 production by dendritic cells resulting in robust listeriosis protection in susceptible mice. This T-cell vaccine approach might be useful for the design of vaccines to protect against listeriosis or other intracellular infections.
Collapse
Affiliation(s)
- Ricardo Calderon-Gonzalez
- Grupo de Genómica, Proteómica y Vacunas, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain
| | - Raquel Tobes
- Information Technologies Research Group, Era7 Bioinformatics, Granada, Spain
| | - Eduardo Pareja
- Information Technologies Research Group, Era7 Bioinformatics, Granada, Spain
| | - Elisabet Frande-Cabanes
- Grupo de Genómica, Proteómica y Vacunas, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain
| | - Nikolai Petrovsky
- Department of Diabetes and Endocrinology, Flinders University, Adelaide, Australia; Vaxine Pty Ltd, Flinders Medical Center, Adelaide, Australia
| | - Carmen Alvarez-Dominguez
- Grupo de Genómica, Proteómica y Vacunas, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
| |
Collapse
|
20
|
Bronchalo-Vicente L, Rodriguez-Del Rio E, Freire J, Calderon-Gonzalez R, Frande-Cabanes E, Gomez-Roman JJ, Fernández-Llaca H, Yañez-Diaz S, Alvarez-Dominguez C. A novel therapy for melanoma developed in mice: transformation of melanoma into dendritic cells with Listeria monocytogenes. PLoS One 2015; 10:e0117923. [PMID: 25760947 PMCID: PMC4356589 DOI: 10.1371/journal.pone.0117923] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Accepted: 01/03/2015] [Indexed: 12/01/2022] Open
Abstract
Listeria monocytogenes is a gram-positive bacteria and human pathogen widely used in cancer immunotherapy because of its capacity to induce a specific cytotoxic T cell response in tumours. This bacterial pathogen strongly induces innate and specific immunity with the potential to overcome tumour induced tolerance and weak immunogenicity. Here, we propose a Listeria based vaccination for melanoma based in its tropism for these tumour cells and its ability to transform in vitro and in vivo melanoma cells into matured and activated dendritic cells with competent microbicidal and antigen processing abilities. This Listeria based vaccination using low doses of the pathogen caused melanoma regression by apoptosis as well as bacterial clearance. Vaccination efficacy is LLO dependent and implies the reduction of LLO-specific CD4+ T cell responses, strong stimulation of innate pro-inflammatory immune cells and a prevalence of LLO-specific CD8+ T cells involved in tumour regression and Listeria elimination. These results support the use of low doses of pathogenic Listeria as safe melanoma therapeutic vaccines that do not require antibiotics for bacterial removal.
Collapse
Affiliation(s)
- Lucia Bronchalo-Vicente
- Grupo de Genómica, Proteómica y Vacunas, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain
- Servicio de Dermatología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
| | - Estela Rodriguez-Del Rio
- Grupo de Genómica, Proteómica y Vacunas, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain
| | - Javier Freire
- Servicio de Anatomía Patológica, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
| | - Ricardo Calderon-Gonzalez
- Grupo de Genómica, Proteómica y Vacunas, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain
| | - Elisabet Frande-Cabanes
- Grupo de Genómica, Proteómica y Vacunas, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain
| | - Jose Javier Gomez-Roman
- Servicio de Anatomía Patológica, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
| | - Hector Fernández-Llaca
- Servicio de Dermatología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
| | - Sonsoles Yañez-Diaz
- Grupo de Genómica, Proteómica y Vacunas, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain
- Servicio de Dermatología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
| | - Carmen Alvarez-Dominguez
- Grupo de Genómica, Proteómica y Vacunas, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain
- * E-mail:
| |
Collapse
|